Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021194985 - ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 6NB6

Publication Number WO/2021/194985
Publication Date 30.09.2021
International Application No. PCT/US2021/023515
International Filing Date 22.03.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
G01N 33/569 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
CPC
A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
42viral
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Applicants
  • CENTIVAX, INC. [US]/[US]
Inventors
  • GLANVILLE, Jacob
  • DARAEIKIA, Shahrad
  • WANG, I-Chieh
  • LIAO CHAN, Sindy Andrea
  • BÜRCKERT, Jean-Philippe
  • YOUSSEF, Sawsan
Agents
  • JAMROZ, Megan
Priority Data
62/993,63023.03.2020US
63/014,51123.04.2020US
63/074,08103.09.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 6NB6
(FR) ANTICORPS ANTI-SRAS-COV-2 DÉRIVÉS DE 6NB6
Abstract
(EN) This disclosure provides antibodies and antigen-binding fragments that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS-CoV-2 infection.
(FR) La présente divulgation concerne des anticorps et des fragments de liaison à l'antigène qui peuvent être administrés à un individu infecté ou suspecté d'être infecté par un virus. Ces anticorps et fragments de liaison à l'antigène peuvent être capables de traiter ou de guérir le virus, et peuvent fournir une protection contre le virus pendant plusieurs semaines. Ces anticorps et fragments de liaison à l'antigène peuvent être utilisés pour diagnostiquer une infection par le SARS-CoV-2.
Latest bibliographic data on file with the International Bureau